Log In
BCIQ
Print this Print this
 

Cuvposa, glycopyrrolate

  Manage Alerts
Collapse Summary General Information
Company Shionogi & Co. Ltd.
DescriptionAnti-cholinergic agent
Molecular Target Muscarinic acetylcholine receptor M1 (CHRM1) (HM1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDrooling
Indication DetailsTreat chronic severe drooling in pediatric patients with neurological conditions
Regulatory Designation U.S. - Orphan Drug (Treat chronic severe drooling in pediatric patients with neurological conditions)
PartnerMerz GmbH & Co. KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/03/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today